PTAB rejected an inter partes review challenge to a key patent protecting the oral multiple sclerosis blockbuster to 2028 in the US, but another challenge remains outstanding.
Biogen's victory over hedge fund manager Kyle Bass' inter partes review (IPR) challenge to a patent protecting its oral multiple sclerosis blockbuster Tecfidera lifts one overhang for the company, but it doesn’t clear the intellectual property headwinds entirely.
On March 21, the US Patent & Trademark Office’s Patent Trial and Appeal Board (PTAB) rejected an IPR challenge against...
Multi-blockbuster falls short in a giant cell arteritis study.
Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.
